BiotechTube

Safinamide, MAO-B inhibitor + Safinamide, MAO-B inhibitor + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Parkinson's Disease

Conditions

Idiopathic Parkinson's Disease

Trial Timeline

Oct 1, 2009 → —

NCT ID
NCT01028586

About Safinamide, MAO-B inhibitor + Safinamide, MAO-B inhibitor + Placebo

Safinamide, MAO-B inhibitor + Safinamide, MAO-B inhibitor + Placebo is a phase 3 stage product being developed by Newron Pharmaceuticals for Idiopathic Parkinson's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01028586. Target conditions include Idiopathic Parkinson's Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01028586Phase 3Terminated

Competing Products

20 competing products in Idiopathic Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77

Other Products from Newron Pharmaceuticals

Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy)Phase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Evenamide 15 mg bid + PlaceboPhase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69